{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T23:02:25Z","timestamp":1648940545355},"reference-count":0,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Neurol"],"published-print":{"date-parts":[[2017,11,1]]},"DOI":"10.1001\/jamaneurol.2017.2142","type":"journal-article","created":{"date-parts":[[2017,10,3]],"date-time":"2017-10-03T22:34:08Z","timestamp":1507070048000},"page":"1294","source":"Crossref","is-referenced-by-count":0,"title":["Which Patients With Ischemic Stroke and Insulin Resistance May Benefit From Pioglitazone Hydrochloride?"],"prefix":"10.1001","volume":"74","author":[{"given":"Graeme J.","family":"Hankey","sequence":"first","affiliation":[{"name":"Medical School, Faculty of Health and Medical Sciences, The University of Western Australia, Perth, Australia2Department of Neurology, Sir Charles Gairdner Hospital, Perth, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","container-title":["JAMA Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/archneur.jamanetwork.com\/article.aspx?doi=10.1001\/jamaneurol.2017.2142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,13]],"date-time":"2017-11-13T17:35:12Z","timestamp":1510594512000},"score":1,"resource":{"primary":{"URL":"http:\/\/archneur.jamanetwork.com\/article.aspx?doi=10.1001\/jamaneurol.2017.2142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,1]]},"references-count":0,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaneurol.2017.2142","relation":{},"ISSN":["2168-6149"],"issn-type":[{"value":"2168-6149","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11,1]]}}}